Cost Curve
everything drug pricing and policy, every day
Connect
Plus Kennedy's nomination is suddenly on solid ground after he made "serious commitments," for what that's worth
BTW: no RFK Jr. references in today's newsletter, but the committee vote is coming in a couple of hours ... so there will be talk tomorrow
Plus a bit on how tariffs are going to worsen, not improve, the issues with generic meds in the United States. And Kennedy nears the end of the beginning.
That's my objective take on his first confirmation hearing, which is not the same as handicapping his chances of confirmation. The two are not remotely connected.
It will be interesting to see if this week's RFK Jr. hearings bring any clarity
Plus warnings from two different groups about the implementation of IRA prices
And there's 340B news, natch, including the latest in the Sagebrush saga plus an estimate of 340B-related tax revenue losses
Plus a definitive list of the nearly two-dozen legal milestones and filings in 340B cases. Going to be a busy winter for the lawyers!
Plus two Health Affairs pieces, one of which is helpful and one of which ... isn't
And the latest on the Sagebrush 340B lawsuits battle makes one thing clear: regardless of the legal niceties, the program is off the rails
And a couple more must-read/must-listen suggestions (as if there haven't been enough of those lately)
And United is committing to 100% rebate passthrough. Should we be impressed?
